Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
K-Dense Web generated a complete competitive intelligence package for CT-388, covering pipeline mapping, receptor pharmacology, clinical efficacy, FAERS safety analysis, SWOT synthesis, and Phase III trial design recommendations
In the STEP 1 trial of 1,961 adults with overweight or obesity, once-weekly semaglutide led to an average weight loss of about 14.9% of body weight over 68 weeks, against 2.4% for placebo
A newer GLP-1 receptor agonist, tirzepatide, demonstrates weight loss as high as 20% change in body weight compared with 3% in the placebo group in a RCT
(Source: The Lancet ) This is the Asian Indian Phenotype : higher body fat percentage, more visceral fat deposition, greater insulin resistance, and elevated cardiovascular risk
US$ 28.73
US$ 24.88
US$ 22.86
US$ 27.16
US$ 24.00
US$ 25.50
US$ 27.30
US$ 26.88
